Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03733691 · ClinicalTrials.gov registry record · Phase 2
Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients
A Phase 2 study, sponsored by Oncotherapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT03733691 is a Phase 2 study that was terminated before completion, run by Oncotherapeutics. The registered enrollment target is 19 participants.
The verdict
NCT03733691, a Phase 2 study, was terminated before completion, sponsored by Oncotherapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a randomized, Phase 2 study involving two arms evaluating the efficacy and safety of ixazomib alone and the combination of both ixazomib and lenalidomide as maintenance therapy for patients with multiple myeloma who have achieved at least partial response (PR) or better after receiving a bortezomib- and lenalidomide-containing combination front-line therapy.
Interventions
- DRUG Lenalidomide
- DRUG Ixazomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2023-10-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03733691
The ClinicalTrials.gov registry entry for NCT03733691 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oncotherapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide is the first listed.
NCT03733691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03733691 about?
NCT03733691 is a clinical study titled "Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients". This is a randomized, Phase 2 study involving two arms evaluating the efficacy and safety of ixazomib alone and the combination of both ixazomib and lenalidomide as maintenance therapy for patients with multiple myeloma who have achieved at least partial response (PR) or better after receiving a bor...
What is the current status of trial NCT03733691?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2019-03-01. Estimated completion is 2023-10-19.
What interventions are being tested in trial NCT03733691?
The interventions under investigation include: Lenalidomide (DRUG), Ixazomib (DRUG).
Who is sponsoring clinical trial NCT03733691?
This trial is sponsored by Oncotherapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.